下子宫部分参与子宫内膜癌的意义
Sharon Davidesko1, Mihai Meirovitz1, Ruthy Shaco-Levy2
1Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Gynecological Oncology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
在子宫内膜癌中,下子宫段参与 (LUSI) 与较差的结果有关,包括较短的无进展生存期 (PFS) 和整体生存期 (OS). 这一发现表明LUSI可能需要考虑辅助治疗决策.
科学领域:
- 妇科瘤学 妇科瘤学
- 病理学 病理学 病理学
- 癌症预后 癌症预后
背景情况:
- 有限的数据表明,子宫内膜癌的下子宫段参与 (LUSI) 可能与不良预后因素相关.
- 对于LUSI对子宫内膜癌预后的确切影响尚不清楚.
研究的目的:
- 研究子宫内膜癌患者下子宫段参与 (LUSI) 和预后之间的关联.
- 确定LUSI是否是总生存期 (OS) 和无进展生存期 (PFS) 的独立预后指标.
主要方法:
- 从429名子宫内膜癌患者 (2002-2022) 的病理样本进行了修订.
- 分析了临床数据和结果,比较了LUSI和没有LUSI的患者.
- 使用Kaplan-Meier生存分析来比较OS和PFS.
主要成果:
- 45名患者 (10.5%) 呈现LUSI,没有显著的人口差异.
- LUSI与淋巴血管空间入侵和淋巴结参与有显著的关联.
- 患有LUSI的患者显示PFS和OS显著缩短,尽管多变量分析没有显著意义.
结论:
- 下子宫段参与 (LUSI) 可能表明子宫内膜癌的预后较差.
- LUSI可能是辅助治疗决策的一个因素,特别是对于子宫内膜类型和早期子宫内膜癌.
更多相关视频
07:44Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
Published on: February 17, 2023
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
相关概念视频
Histology of the Uterus
The endometrium is the...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
